Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novo Acquires Norway’s Xellia
by Ann M. Thayer
May 27, 2013
| A version of this story appeared in
Volume 91, Issue 21
Denmark’s Novo has paid private investors $700 million to acquire Xellia Pharmaceuticals, a Norwegian anti-infectives firm. Since its 2008 spin-off from Alpharma, Xellia has shifted from making active ingredients to selling fermented and semisynthetic finished drugs. It had revenues of $220 million last year. Xellia says Novo’s investment will allow it to focus on R&D and to expand manufacturing. Novo manages the assets of the $30 billion Novo Nordisk Foundation and is the major shareholder in Novo Nordisk, Novozymes, and Chr. Hansen.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter